FOLH1 and prostate cancer: Screening for the VISION trial using 177Lu-PSMA-617 radioligand therapy (RLT) in metastatic castration-resistant prostate cancer excluded approximately 12% of patients due to missing or low PSMA expression of known tumor lesions in 68 Ga-PSMA11-PET [24].